Use of C-reactive protein for prediction of sinus rhythm maintenance after pharmacologic cardioversion in patients with Metabolic Syndrome
Approximately 50% of patients undergoing cardioversion present with a recurrence of Atrial Fibrillation ( AF) within 3-6 months of cardioversion despite ongoing antiarrhythmic treatment (AAD). Inflammation has been involved in the pathogenesis of both metabolic syndrome (MS) and atrial fibrillation....
Saved in:
Main Authors: | Jani Ylber (Author), Neziri Entela (Author), Paparisto Sokol (Author), Bara Petrit (Author), Haxhirexha Kastriot (Author), Pocesta Bekim (Author), Rexhepi Atila (Author), Xhunga Sotiraq (Author), Serani Artur (Author), Ferati Fatmir (Author), Zeqiri Agim (Author), Kamberi Ahmet (Author) |
---|---|
Format: | Book |
Published: |
Sciendo,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019) -
Early childhood caries in preschool children of Kosovo - a serious public health problem
by: Meqa Kastriot, et al.
Published: (2010) -
PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015) -
PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015) -
Efficiency and safety of pharmacological cardioversion for atrial fibrillation
by: Aleksei V. Tarasov
Published: (2021)